Pilot Study of Bumetanide for Newborn Seizures

Completed · Phase 1 · Has a placebo group

Conditions studied: Seizures

In brief

The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone.

Key facts

Study ID
NCT00830531
Run by
Soul, Janet , M.D.
People needed
43
Starts
2010-01-01
Expected to finish
2019-01-01
Last updated by the study team
2020-12-17

Who can join

Age: any, up to 1. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.